Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Otsuka to Buy Avanir for $3.5B

By Pharmaceutical Processing | December 2, 2014

Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker’s portfolio of neurologic disease treatments.

Avanir shareholders will receive $17 per share, according to the agreement announced Tuesday. That represents a 13 percent premium over Avanir’s closing price Monday.

Avanir makes Nuedexta, which treats a condition called pseudobulbar affect. The ailment is tied to diseases like multiple sclerosis or traumatic brain injuries and involves involuntary emotional outbursts such as laughing or crying. Nuedexta, which Avanir launched in the United States in 2011, brought in $94 million in revenue in the year that ended last June.

Avanir Pharmaceuticals Inc., based in Aliso Viejo, California, was founded in 1988 and employs about 500 people. It also has developed a treatment, now in late-stage testing, for agitation associated with Alzheimer’s disease. Its pipeline of drugs under development also includes potential Parkinson’s disease and migraine treatments.

Otsuka Pharmaceutical Co. Ltd. employs more than 28,000 people and is a subsidiary of Otsuka Holdings Co. Ltd.

The boards of both companies have approved the deal, which is expected to close in next year’s first quarter.

Shares of Avanir jumped nearly 13 percent, or $1.91, to $16.91 Tuesday, hours before markets opened. The stock has soared since closing 2013 at $3.36.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE